analyzing the survival benefits of niraparib dose modification in ovarian cancer
Published 5 years ago • 231 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
2:26
dr. mirza discusses niraparib dose modifications for ovarian cancer patients with low body weight
-
1:54
management of niraparib dosing in ovarian cancer
-
4:29
case 1: use of niraparib in ovarian cancer
-
2:35
clinical use of niraparib in ovarian cancer
-
1:50
niraparib shows positive data, requires different dosing in ovarian cancer
-
6:32
case 1: use of niraparib in ovarian cancer
-
0:43
efficacy of niraparib on pfs in patients with recurrent ovarian cancer
-
1:42
final ananova2 survival data support niraparib plus bevacizumab in recurrent ovarian cancer
-
3:14
personalized dosing of niraparib in ovarian cancer
-
3:10
overview of engot-ov16/nova of niraparib in ovarian cancer and why the results were not surprising
-
1:48
niraparib maintenance therapy in ovarian cancer
-
7:19
combination therapy with niraparib and bevacizumab for ovarian cancer
-
2:11
design of the nova trial for ovarian cancer
-
3:08
ovarian cancer: optimizing treatment with niraparib
-
3:23
niraparib significantly improves outcomes for ovarian cancer patients
-
3:51
the future of care in advanced ovarian cancer
-
6:02
pfs increase but no os increase for niraparib in advanced ovarian cancer
-
6:52
case 3: benefit of parp inhibitor maintenance in ovarian cancer
-
6:55
deciding on treatment for epithelial ovarian cancer